ArticleAJNR. American journal of neuroradiology2005
Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D?
Article in AJNR. American journal of neuroradiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.Neurology · 2016Guideline
- Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.AJNR. American journal of neuroradiology · 2019Trial
- Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.Neuro-oncology · 2018Trial
- Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.Neuro-oncology · 2017Trial
- Adaptation of a Brain-Dedicated Multipinhole SPECT System for Imaging Higher-Energy Photons of Theranostic Agents-A Simulation Study.IEEE transactions on radiation and plasma medical sciences · 2026Article
- Precision tumor targeting: gamma-irradiated ellagic acid therapy for ferroptosis and necroptosis modulation via GPX4/ALOX/RIPK/MLKL pathway inhibition.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Development and Evaluation of Automated Artificial Intelligence-Based Brain Tumor Response Assessment in Patients with Glioblastoma.AJNR. American journal of neuroradiology · 2025Article
- RANO criteria for response assessment of brain metastases based on amino acid PET imaging.Nature medicine · 2025Review
- Shape matters: unsupervised exploration of IDH-wildtype glioma imaging survival predictors.European radiology · 2025Article
- Heterogeneous multiple soft millirobots in three-dimensional lumens.Science advances · 2024Article
- Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.Neuro-oncology · 2024Article
- Artificial Intelligence Analysis Using MRI and PET Imaging in Gliomas: A Narrative Review.Cancers · 2024Review
- "A net for everyone": fully personalized and unsupervised neural networks trained with longitudinal data from a single patient.BMC medical imaging · 2023Article
- Disease Assessments in Patients with Glioblastoma.Current oncology reports · 2023Review
- Mapping early tumor response to radiotherapy using diffusion kurtosis imaging*.The neuroradiology journal · 2023Article
- Changes in Oncogene Expression in Experimental Glioblastoma 101.8 Rats during Therapy with PLGA Nanoparticles Loaded with Doxorubicin.Bulletin of experimental biology and medicine · 2023Article
- Evaluation of the HD-GLIO Deep Learning Algorithm for Brain Tumour Segmentation on Postoperative MRI.Diagnostics (Basel, Switzerland) · 2023Article
- Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration.Frontiers in radiology · 2023Review
- Brain tumour segmentation with incomplete imaging data.Brain communications · 2023Article
- Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry.Neuro-oncology · 2022Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeTumor "size" is used internationally as a surrogate marker for overall survival when following current response assessment protocols (World Health Organization and Response Evaluation Criteria in Solid Tumors). With little evidence of a relationship between tumor "size" and survival in intrinsic brain tumors, this study was undertaken to investigate the predictive value of MR imaging-defined tumor size for survival in patients with recurrent malignant glioma and to compare the different measures of tumor size used in these current response assessment protocols.
methodsVolumetric, bidimensional, and unidimensional measurements of tumor size were made using baseline contrast-enhanced T1-weighted images of 70 patients with recurrent malignant glioma receiving intravenous chemotherapy. Cox's proportional hazards model was used to investigate the prognostic importance of tumor size using survival as the end point. Further statistical analysis was undertaken to investigate the relationship between the different measurement techniques.
resultsOnly the volumetric measurement of tumor size was found to be predictive of survival in recurrent malignant glioma on both univariate and multivariate analysis. Furthermore, analysis demonstrated that the unidimensional and bidimensional measures of tumor were not comparable with the more accurate and direct volumetric measurement.
conclusionIndirect unidimensional and bidimensional measurement techniques do not have a significant association with overall survival or adequately assess tumor size in recurrent malignant glioma. These findings have serious implications about the validity of using current response assessment protocols in therapy trials for recurrent malignant glioma.
Indexed as
Identifiers
15814919PMC7977136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.